Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165087 · ClinicalTrials.gov registry record · Phase 3
Treatment of Childhood Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 491
- Enrollment target
NCT00165087: Clinical Trial Phase 3 study, sponsored by Dana-Farber Cancer Institute.
NCT00165087 is a Phase 3 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 491 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00165087, a Phase 3 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 491 participants
- Enrollment target
Study Summary
The purpose of this study is to reduce the side-effects and discomfort of anti-leukemia therapy, to attain long-term control of the disease and to hopefully eradicate it.
Interventions
- DRUG doxorubicin
- DRUG asparaginase (E. Coli)
- DRUG asparaginase (Erwina)
- DRUG dexrazoxane
- PROCEDURE cranial radiation (once daily fractionation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 1996-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Why NCT00165087 stopped before completion
NCT00165087 is an interventional study that assigns participants to a tested intervention. The registered 491 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 5 interventions - of which doxorubicin is the first listed.
NCT00165087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00165087 about?
NCT00165087 is a clinical study titled "Treatment of Childhood Acute Lymphoblastic Leukemia". The purpose of this study is to reduce the side-effects and discomfort of anti-leukemia therapy, to attain long-term control of the disease and to hopefully eradicate it.
What is the current status of trial NCT00165087?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 491 participants. The study started on 1996-01. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00165087?
The interventions under investigation include: doxorubicin (DRUG), asparaginase (E. Coli) (DRUG), asparaginase (Erwina) (DRUG), dexrazoxane (DRUG), cranial radiation (once daily fractionation) (PROCEDURE).
Who is sponsoring clinical trial NCT00165087?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00165087's enrollment target sits among peer trials
491 781st of 2000 higher than 1,219 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03418961 · 491 participants · Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia